En la vasta sinfonía del mundo natural, algunos sonidos apenas son perceptibles para el oído humano, mientras que otros escapan completamente a nuestra capacidad auditiva. Desde los infrasonidos provocados por fenómenos geológicos hasta los chillidos ultrasónicos d …
Los sonidos más graves y más agudos de la naturaleza Read More »
Durante décadas, el colesterol ha sido demonizado como el principal culpable de enfermedades cardiovasculares. Sin embargo, su papel en el cerebro es mucho más complejo, y cada vez más investigaciones científicas revelan que este lípido es esencial para el funciona …
This year, LOTTE BIOLOGICS has ramped up its CDMO business expansion with the completion of an ADC (Antibody-Drug Conjugate) facility expansion at its Syracuse Bio Campus in the U.S. and the signing of its first production contract.
A ripple effect of the NIH’s slashed 2026 budget will be felt throughout the biopharma ecosystem. Young companies must act now to weather the storm.
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy families have turned to the news for answers. Meanwhile, the FDA insists it remains committed to notifying companies of any regulatory action before sharing information with the media or public.
‘Unprecedented’ FDA Leaks Sow Confusion For Patients, Sarepta and Capricor Read More »
After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma research is entering a new phase spurred by smarter trials, targeted funding and renewed interest from companies like Merck and Jazz Pharmaceuticals.
Glioblastoma Funding Rises as Nonprofits Drive Interest and Pharma Returns to the Table Read More »
The regulation should enable workflow automation that could limit paperwork burdens on providers, regulators said.
ASTP finalizes HTI-4 rule on prior authorization, electronic prescribing Read More »
From, who joins the surgical robot developer from Aruna Bio, will take the reins from co-founder Adam Sachs on Aug. 7.
Vicarious Surgical names Stephen From as next CEO Read More »
The medtech firm, which previously forecast a $200 million tariff impact for 2025, also raised its earnings outlook, citing strength in procedure demand.
Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO Leonard Schleifer told investors.
Regulatory Roadblocks Blemish Regeneron’s Otherwise Strong Q2 Read More »
